Comment on stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma—Authors’ reply
Corresponding Author
Ting-Shi Su MMed
Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Cyberknife Center, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Correspondence to: Ting-Shi Su, MMed, and Ping Liang, MMed, Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning 530001, Guangxi Zhuang Autonomous Region, China. Fax: +86-0771-2250120. E-mail: [email protected]
Search for more papers by this authorPing Liang MMed
Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Cyberknife Center, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Search for more papers by this authorHuan-Zhen Lu BMed
Cyberknife Center, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Search for more papers by this authorJian Liang MD
Department of Gastroenterology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Search for more papers by this authorYing-Chuan Gao MMed
Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Search for more papers by this authorYing Zhou MMed
Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Search for more papers by this authorYong Huang MMed
Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Search for more papers by this authorMin-Yang Tang MMed
Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Search for more papers by this authorJian-Ning Liang BMed
Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Search for more papers by this authorCorresponding Author
Ting-Shi Su MMed
Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Cyberknife Center, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Correspondence to: Ting-Shi Su, MMed, and Ping Liang, MMed, Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning 530001, Guangxi Zhuang Autonomous Region, China. Fax: +86-0771-2250120. E-mail: [email protected]
Search for more papers by this authorPing Liang MMed
Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Cyberknife Center, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Search for more papers by this authorHuan-Zhen Lu BMed
Cyberknife Center, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Search for more papers by this authorJian Liang MD
Department of Gastroenterology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Search for more papers by this authorYing-Chuan Gao MMed
Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Search for more papers by this authorYing Zhou MMed
Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Search for more papers by this authorYong Huang MMed
Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Search for more papers by this authorMin-Yang Tang MMed
Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Search for more papers by this authorJian-Ning Liang BMed
Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
Search for more papers by this author
REFERENCES
- 1 Su TS, Liang P, Lu HZ, et al.: Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients. J Surg Oncol 2016; 113: 181–187.
- 2 Liu L, Zhang QS, Pan LH, et al.: Subclassification of patients with solitary hepatocellular carcinoma based on post-hepatectomy survival: A large retrospective study. Tumour Biol 2016; 37: 5327–5335.
- 3 Shiozawa K, Watanabe M, Ikehara T, et al.: Comparison of percutaneous radiofrequency ablation and CyberKnife((R)) for initial solitary hepatocellular carcinoma: A pilot study. World J Gastroenterol 2015; 21: 13490–13499.
- 4 Yuan Z, Tian L, Wang P, et al.: Comparative research on the efficacy of CyberKnife(R) and surgical excision for Stage I hepatocellular carcinoma. Onco Targets Ther 2013; 6: 1527–1532.
- 5 Wahl DR, Stenmark MH, Tao Y, et al.: Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol 2016; 34: 452–459.
